Author's response to reviews

Title: Onset of Efficacy and Tolerability Following the Initiation Dosing of Long-Acting Paliperidone Palmitate: Post-Hoc Analyses of a Randomized, Double-Blind Clinical Trial

Authors:

Cynthia A Bossie (cbossie@its.jnj.com)
Jennifer K Sliwa (jkernsli@its.jnj.com)
Yi-Wen Ma (yma@its.jnj.com)
Dong-Jing Fu (dfu@its.jnj.com)
Larry Alphs (lalphs@its.jnj.com)

Version: 2 Date: 26 October 2010

Author's response to reviews:

In the revised manuscript we have added additional details regarding how the doses of paliperidone palmitate may be expressed. Please see page 4 of introduction where we added the following sentences--"The dosing of paliperidone palmitate may be expressed in terms of milligrams of paliperidone palmitate or in terms of milligram equivalents (mg eq) of the pharmacologically active fraction, paliperidone. Paliperidone palmitate expressed as 39, 156 mg and 234 mg is equivalent to 25, 100, and 150 mg eq, respectively, of the active fraction paliperidone." Also, we slightly revised the text in the second sentence of the Study Medications first paragraph to clarify the dosing expression of paliperidone palmitate. Specifically, the sentence "Eligible patients were randomly assigned (1:1:1:1) to fixed doses of paliperidone palmitate 39 mg, 156 mg, or 234 mg (equivalent to 25, 100, or 150 mg eq of the active fraction paliperidone), or placebo, based on a computer-generated randomization schedule balanced by using permuted blocks of treatments and stratified by center." was revised slightly.